OakChart

Beyond Air Inc

XAIRHealthcare·Medical Devices·USA·Nano·NASD·Nov 11 • 3:59 PM ET

2.63+0.11 (4.37%)
2026-11-12 02:32 CET
Market cap
4.20 USD m
Revenue, TTM
7.69 USD m
Net income, TTM
-33.49 USD m
Free cash flow, TTM
-19.60 USD m
EPS diluted, TTM
-68.49
P/E
-
Compare

Price

XAIR against its 20, 50 and 200-day averages
2050200missearnings
10.0020.0030.004.4M8.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26XAIRclose 2.6320-day 2.2750-day 2.66200-day 9.222.63

95.1% under the 52-week high of 53.20 on 13 Jan 2026. 52-week low 2.05 on 14 Oct 2026. Last 15 sessions, 70.2% high to low

Volume 3.26× normal · the line is the 50-bar volume average

Profile

XAIR
52-week range, 1% of the way up
2.0553.20

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air, Beyond Cancer segments, and NeuroNos. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.

Employees54
IPOSep 23, 2016
Beta0.27
ATR, 14d0.28
Rel volume3.26
Short float5.29%
Insider own15.03%
Inst own4.25%

Snapshot

6 groups

Valuation

Index-
Market Cap4.38M
Enterprise Value13.60M
Income-33.49M
Sales7.69M
Book/sh2.69
Cash/sh9.13
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees54
IPOSep 23, 2016

Ratios

P/E-
Forward P/E-
PEG-
P/S0.57
P/B0.98
P/C0.29
P/FCF-
EV/EBITDA-
EV/Sales1.77
Quick Ratio3.12
Current Ratio3.31
Debt/Eq11.80
LT Debt/Eq11.57
Option/ShortNo / Yes

Earnings

EPS (ttm)-68.49
EPS next Y-
EPS next Q-2.23
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y52.44% 30.89%
Sales past 3/5Y- 54.47%
EPS Y/Y TTM71.34%
Sales Y/Y TTM60.75%
EPS Q/Q64.13%
Sales Q/Q0.45%
EarningsNov 11 AMC
EPS/Sales Surpr.-13.60% 7.44%

Ownership

Insider Own15.03%
Insider Trans32.92%
Inst Own4.25%
Inst Trans0.02%
ROA-109.80%
ROE-561.77%
ROIC-133.22%
Gross Margin4.18%
Oper. Margin-364.76%
Profit Margin-435.71%
SMA2016.07%
SMA50-0.97%
SMA200-71.49%
Trades-

Technical

Shs Outstand1.67M
Shs Float1.42M
Short Float5.29%
Short Ratio0.35
Short Interest0.08M
52W High53.20 -95.06%
52W Low2.05 28.29%
Volatility16.75% 9.99%
ATR (14)0.28
RSI (14)56.25
Beta0.27
Rel Volume3.26
Avg Volume213.59K
Volume696,688

Performance

Perf Week12.88%
Perf Month20.09%
Perf Quarter-61.99%
Perf Half Y-75.55%
Perf YTD-81.89%
Perf Year-90.99%
Perf 3Y-99.68%
Perf 5Y-99.94%
Perf 10Y-99.98%
Recom1.00
Target Price18.33
Prev Close2.52
Price2.63
Change %4.37%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Sep 01, 2026InitiatedLLake StreetBuy$10+280.2%
Jul 17, 2025InitiatedDD. Boral CapitalBuy$11+318.3%
Jun 25, 2024DowngradeBBTIG ResearchBuy → Neutral
Jul 28, 2023InitiatedPPiper SandlerOverweight$10+280.2%
Jun 15, 2023InitiatedBBTIG ResearchBuy$15+470.3%
Apr 28, 2021InitiatedTTruistBuy$12+356.3%
Oct 22, 2019InitiatedOOppenheimerOutperform$9+242.2%

Peers

Mkt cap
TickerCompanyMkt cap
NUWENuwellis Inc2.99M
INGNInogen Inc149.51M
CTSOCytosorbents Corp16.83M
ELMDElectromed Inc206.84M
LUNGPulmonx Corp129.78M
VMDViemed Healthcare Inc345.96M
AEMDAethlon Medical Inc8.87M
OWLTOwlet Inc134.42M
LQDALiquidia Corp4.94B
UTHRUnited Therapeutics Corp25.37B

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Lin Yi-Chien10% OwnerOct 13 '26Buy2.212,6075,761148,000Oct 14 12:14 PM
Lin Yi-Chien10% OwnerOct 01 '26Buy2.8015,39343,100145,393Oct 02 08:24 PM
Lin Yi-Chien10% OwnerSep 29 '26Buy2.693,0008,070128,000Oct 02 08:24 PM
Lin Yi-Chien10% OwnerSep 30 '26Buy2.712,0005,420130,000Oct 02 08:24 PM
Goodman Robert ScottChief Executive OfficerJul 29 '26Buy5.7634,722199,99934,822Jul 31 06:55 PM
MOORHEAD DANIEL JChief Financial OfficerJul 29 '26Buy5.764,34024,9984,340Jul 31 06:21 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 99
  • Beyond Air Reports Financial Results and Provides Corporate Update for the Quarter Ended September 30, 2026 (GlobeNewswire)
  • Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026 (GlobeNewswire)
  • Beyond Air Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026 (GlobeNewswire) -9.06%
  • Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference (GlobeNewswire)
  • Beyond Air Receives FDA Breakthrough Device Designation for LungFit GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) (GlobeNewswire) -11.38%
  • Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments (GlobeNewswire)
  • Beyond Air Inc (XAIR) (Q1 2027) Earnings Call Highlights: Strategic Financing and Pipeline ... (GuruFocus.com) +14.38% -8.74%
  • Beyond Air Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update (GlobeNewswire)
  • Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026 (GlobeNewswire)
  • Beyond Air Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
  • Beyond Air Inc (XAIR) Q4 2026 Earnings Call Highlights: Revenue Surge and Path to Profitability (GuruFocus.com)
  • Beyond Air Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast (GlobeNewswire) +13.61% +14.43%
  • Beyond Air, Inc. Urges Stockholders to Vote "FOR" All Proposals Ahead of the Upcoming Special Meeting (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-11-11-3.760-3.310-3.7602.322.162
2026Q12026-08-13-11.000-10.800-11.0001.771.931
2025Q42026-06-26-15.400-11.333-15.4761.912.303
2025Q32026-02-13-17.000-15.010-17.0272.192.154
2025Q22025-11-10-25.000-15.466-24.9821.822.153
2025Q12025-08-12-30.600-24.560-30.6721.762.595
2024Q42025-06-17-36.000-48.800-35.7201.151.385
2024Q32025-02-10-60.000-63.760-59.1881.070.945
2024Q22024-11-11-112-113.6-113.40.801.035
2024Q12024-08-09---106.320.68--
2023Q42024-06-24-144-189.6-142.870.470.745
2023Q32024-02-12-200-216-199.860.390.455
2023Q22023-11-13-204-187.64-204.020.240.486
2023Q12023-08-10-180-186.68-179.650.060.336
2022Q42023-06-22-264-194-262.430.000.534
2022Q32023-02-09-172-165.6-170.410.000.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-504-185.32-308.697.726.63
2019FY-712-728-711.441.391.90
2020FY-508-533.6-508.180.870.97
2021FY-672-484.8-672.850.000.00
2022FY-744-670-744.870.000.53
2023FY-728-773.6-726.681.161.43
2024FY-276-296.8-2763.713.91
2025FY-80.200-75.467-80.2007.688.08
2026FY-----
2027FY-----
2028FY-----
2029FY--8.600--75.94

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-112012.252.202.31
2026Q3S2026-10-272012.252.202.31
2026Q3S2026-10-082112.252.202.31
2026Q3S2026-08-312102.302.302.31
2026Q3S2026-08-131102.312.312.31
2026Q3S2026-08-071002.122.122.12
2026Q3S2026-07-191003.073.073.07
2026Q3S2026-07-012012.212.122.30
2026Q3S2026-06-262002.712.123.30
2026Q3S2026-05-262002.611.933.30
2026Q3S2026-05-183003.321.934.73
2026Q3S2026-05-043005.624.006.74
2026Q3S2026-04-293103.321.934.73
2026Q3S2026-04-103113.321.934.73

Estimate history

EPS, annual-1204-308.688-711.44-508.18-672.848-744.868-726.68-275.452-80.109-68.4852
Period201720182019202020212022202320242025TTM
EPS, quarterly-106.324-113.4-59.188-35.72-30.672-24.982-17.027-15.476-11.001
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Sales, annual07.7241.390.873001.1593.7057.6797.69
Period201720182019202020212022202320242025TTM
Sales, quarterly0.6830.7981.0721.1521.761.8182.1941.9071.768
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Shares, annual0.0150.0220.040.0550.0750.0770.1150.2060.590.743
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.1150.180.1860.2060.2350.40.420.590.743
PeriodQ1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue7.697.683.711.160.000.000.871.397.72
Cost of Goods Sold Incl. D&A7.377.435.372.471.730.59--0.06
Gross Profit0.320.25-1.66-1.31-1.73-0.59--7.66
Selling, General and Administrative Excl. Other28.3629.3042.8761.7050.3329.6222.8419.3110.72
Research and Development9.1110.2416.8624.3616.8111.8012.6210.653.93
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-28.04-29.04-44.54-63.01-52.06-30.21-22.21-18.14-3.06
Interest Expense4.463.523.022.910.030.780.640.03-
Unusual Expense1.691.520.90-0.067.8612.940.000.000.00
Net Income Before Taxes-34.41-34.33-48.48-64.30-59.40-44.06-22.87-20.10-6.56
Income Taxes0.000.000.000.000.000.000.00-0.150.00
Consolidated Net Income-34.41-34.33-48.48-64.30-59.40-44.06-22.87-19.94-6.56
Net Income From Continuing Operations-33.49-33.25-46.62-60.24-55.82-43.18-22.87-19.94-6.56
Net Income-33.49-33.25-46.62-60.24-55.82-43.18-22.87-20.46-6.56
EPS (Recurring)-44.79-77.54-271.75-727.19-671.42-531.75-508.18-711.44-308.69
EPS (Basic, Before Extraordinaries)-68.49-80.11-275.45-726.68-744.87-672.85-508.18-711.44-308.69
EPS (Diluted)-68.49-80.11-275.45-726.68-744.87-672.85-508.18-711.44-308.69
EBITDA-24.40-25.39-40.97-60.66-50.89-29.62-21.96-17.92-2.99
Non-Operating Income (Expense)-0.22-0.25-0.031.560.55-0.14-0.02-1.92-3.50
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.745.289.1521.3419.567.833.572.612.55
Price To Sales Ratio0.840.754.9849.78--113.4166.225.28
Gross Margin4.183.28-44.89-112.77----99.16
Operating Margin-364.76-378.23-1,202.08-5,436.32---2,543.95-1,305.08-39.60
Net Margin-435.71-432.99-1,258.43-5,197.76---2,619.67-1,472.19-84.91
Shares Outstanding0.740.590.210.110.080.070.050.040.02
Market Capitalization4.204.2022.5061.73207.49199.51120.06128.4540.96

Income statement, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q2
Total Revenue1.771.912.191.821.761.151.070.80
Cost of Goods Sold Incl. D&A1.541.811.892.121.601.181.291.88
Gross Profit0.230.090.30-0.300.16-0.03-0.21-1.08
Selling, General and Administrative Excl. Other6.847.266.907.367.777.1410.7411.75
Research and Development1.962.282.432.453.093.263.004.58
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.61-7.17-6.60-7.66-7.62-7.17-10.95-12.83
Interest Expense1.491.241.090.640.550.580.550.93
Unusual Expense0.152.04-0.500.00-0.02-0.101.910.37
Net Income Before Taxes-8.15-10.37-7.63-8.26-8.08-8.06-13.33-14.03
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-8.15-10.37-7.63-8.26-8.08-8.06-13.33-14.03
Net Income From Continuing Operations-7.93-10.28-7.34-7.94-7.69-8.04-13.03-13.36
Net Income-7.93-10.28-7.34-7.94-7.69-8.04-13.03-13.36
EPS (Recurring)-10.85-13.32-17.84-24.98-30.72-36.05-53.13-111.19
EPS (Basic, Before Extraordinaries)-11.00-15.48-17.03-24.98-30.67-35.72-59.19-113.40
EPS (Diluted)-11.00-15.48-17.03-24.98-30.67-35.72-59.19-113.40
EBITDA-5.69-6.25-5.70-6.75-6.69-6.23-10.10-11.89
Non-Operating Income (Expense)0.100.09-0.450.040.07-0.420.070.10
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.040.431.501.771.580.162.483.13
Price To Sales Ratio0.841.190.902.533.616.6210.447.81
Gross Margin12.734.9313.67-16.398.86-2.69-20.06-135.84
Operating Margin-373.98-375.98-300.64-421.40-432.78-622.66-1,021.64-1,608.02
Net Margin-448.81-539.17-334.37-436.74-436.99-697.48-1,215.67-1,673.93
Shares Outstanding0.740.590.420.400.230.210.190.18
Market Capitalization4.208.146.1018.5016.1722.5026.6528.01

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments17.267.1534.7056.0190.2335.2725.477.901.81
Short Term Receivables1.190.860.550.650.600.420.000.000.00
Inventories1.412.422.131.130.350.000.000.000.00
Other Current Assets4.915.596.561.621.761.531.220.790.11
Total Current Assets24.7716.0243.9459.4192.9437.2226.688.691.92
Net Property, Plant & Equipment9.4412.7211.487.504.212.790.340.240.27
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets1.021.221.431.631.840.370.410.490.00
Other Assets0.160.100.110.210.210.140.000.000.00
Total Assets35.3830.0656.9668.7599.2040.5327.439.432.19
Short Term Debt Incl. Current Port. of LT Debt0.721.001.221.151.210.670.400.300.03
Accounts Payable2.421.951.952.021.131.322.261.160.00
Income Tax Payable------0.000.150.15
Other Current Liabilities3.372.048.4016.618.381.802.213.791.21
Total Current Liabilities6.515.0011.5719.7810.713.804.875.401.40
Long Term Debt22.6610.6816.622.442.286.264.470.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.041.594.508.000.000.000.009.17
Total Liabilities29.1815.7229.7726.7220.9910.069.345.4010.57
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity6.1313.5825.0537.9172.7030.4618.094.02-8.38
Total Shareholders Equity6.1313.5825.0537.9172.7030.4618.094.02-8.38
Accumulated Minority Interest0.080.762.144.115.500.000.000.000.00
Total Equity6.2114.3427.1942.0378.2130.4618.094.02-8.38
Total Liabilities & Stockholders Equity35.3830.0656.9668.7599.2040.5327.439.432.19
Book Value Per Share10.3965.80218.28493.39973.73558.25450.72184.74-549.69
Tangible Book Value Per Share8.6659.88205.84472.15949.13551.38440.44162.02-549.69
Full-Time Employees5461107987041231812
Price to Book Ratio0.941.662.975.472.743.947.1016.68-4.43
Return on Assets-101.61-107.16-95.84-66.47-61.80-67.32-108.20-112.91-
Return on Equity-337.40-241.39-191.36-100.92-83.70-94.22-180.33--
Return on Invested Capital-115.50-192.14-144.58-138.31-57.58-62.29-88.39-162.95-
Quick Ratio3.592.723.612.958.649.805.481.611.38
Current Ratio3.803.203.803.008.689.805.481.611.38

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-34.41-34.33-48.48-64.30-59.40-44.06-22.87-19.94-6.56
Depreciation3.643.653.572.351.170.590.250.220.06
Other Funds (Non Cash)10.4910.2012.8421.9719.838.505.065.535.70
Funds from Operations-20.28-20.49-32.07-39.98-38.40-34.97-17.56-14.19-0.79
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.722.35-6.15-16.045.3911.84-2.08-1.132.13
Cash from Operating Activities-18.56-18.14-38.22-56.02-33.01-23.13-19.64-15.321.34
Capital Expenditures-1.03-1.02-5.88-5.75-3.88-1.38-0.89-0.04-0.06
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-2.83-2.6520.78-6.49-16.710.000.004.47-1.74
Purchase of Investments-4.09-4.05-30.88-128.77-35.660.000.00-37.32-12.22
Sale Or Maturity of Investments1.261.4051.66122.2818.950.000.0041.7910.49
Other Uses0.000.000.000.000.00-0.070.000.000.00
Other Sources0.070.000.010.000.000.000.000.000.00
Cash from Investing Activities-3.79-3.6714.90-12.23-20.59-1.45-0.894.42-1.79
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock13.8516.2923.3728.183.7179.0430.1129.930.81
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock13.8516.2923.3728.183.7179.0430.1129.930.81
Proceedsfrom Stock Options6.488.934.1527.973.7172.830.0025.750.80
Issuance or Reduction of Debt, Net11.0012.80-6.7314.98-1.010.370.225.070.26
Change in Long Term Debt11.0013.0011.320.000.000.000.000.000.00
Issuance of Long Term Debt11.0013.0011.320.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow3.230.000.000.000.000.040.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities28.0829.0916.6543.172.7079.4530.3335.011.07
Exchange Rate Effect0.050.19-0.04-0.08-0.040.10---
Net Change in Cash5.787.47-6.71-25.16-50.9454.969.8024.110.62
Free Cash Flow-19.60-19.17-44.10-61.76-36.89-24.51-20.53-15.361.28
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00-0.00
Price to Free Cash Flow--------31.76
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Cash & Short Term Investments15.2217.2617.8510.866.637.15
Short Term Receivables1.231.191.260.971.020.86
Inventories1.291.411.762.232.432.42
Other Current Assets5.114.914.704.534.915.59
Total Current Assets22.8524.7725.5618.5914.9916.02
Net Property, Plant & Equipment8.989.449.9710.9511.8412.72
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.971.021.071.121.171.22
Other Assets0.090.160.170.310.110.10
Total Assets32.8935.3836.7730.9628.1130.06
Short Term Debt Incl. Current Port. of LT Debt0.450.720.390.410.651.00
Accounts Payable2.462.422.201.921.241.95
Other Current Liabilities4.003.372.402.062.742.04
Total Current Liabilities6.916.514.994.384.635.00
Long Term Debt23.1422.6623.2011.3811.0410.68
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.292.102.040.04
Total Liabilities30.0529.1828.4917.8717.7115.72
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity2.006.138.1112.739.9313.58
Total Shareholders Equity2.006.138.1112.739.9313.58
Accumulated Minority Interest0.840.080.170.360.480.76
Total Equity2.846.218.2913.1010.4114.34
Total Liabilities & Stockholders Equity32.8935.3836.7730.9628.1130.06
Book Value Per Share2.6910.3919.3031.7942.3065.80
Tangible Book Value Per Share1.398.6616.7629.0037.3159.88
Full-Time Employees-54---61
Price to Book Ratio0.941.330.751.451.631.66
Return on Assets-109.80-101.61-87.43-87.40-112.89-107.16
Return on Equity-561.77-337.40-240.75-179.63-323.27-241.40
Return on Invested Capital-31.56-35.72-23.43-32.92-36.68-33.11
Quick Ratio3.123.594.773.732.712.72
Current Ratio3.313.805.124.243.243.20

Cash flow, quarterly

Currency USD, millions
Metric2026Q12025Q42025Q32025Q22025Q12024Q4
Net Income-8.15-10.37-7.63-8.26-8.08-8.06
Depreciation0.920.920.890.920.930.94
Other Funds (Non Cash)2.273.482.262.481.981.24
Funds from Operations-4.96-5.98-4.48-4.86-5.17-5.88
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.011.030.260.410.65-1.07
Cash from Operating Activities-4.95-4.95-4.22-4.45-4.53-6.96
Capital Expenditures-0.21-0.55-0.03-0.25-0.20-1.50
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.600.10-4.010.490.774.08
Purchase of Investments-0.04-0.04-4.010.00-0.000.00
Sale Or Maturity of Investments0.640.140.000.490.784.08
Other Uses0.000.000.000.000.000.00
Other Sources0.070.000.000.000.000.00
Cash from Investing Activities0.46-0.45-4.040.240.582.58
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.004.500.209.152.443.87
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.004.500.209.152.443.87
Proceedsfrom Stock Options0.00-2.780.209.062.443.51
Issuance or Reduction of Debt, Net-0.170.4011.00-0.231.620.63
Change in Long Term Debt0.000.0011.000.002.000.00
Issuance of Long Term Debt0.000.0011.000.002.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow3.230.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.064.9011.218.924.074.50
Exchange Rate Effect-0.020.020.030.020.13-0.06
Net Change in Cash-1.45-0.472.974.720.240.06
Free Cash Flow-5.15-5.49-4.25-4.70-4.72-8.46

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 3.71M 2025: 7.68M
United States2024: 3.71M 2025: 7.68M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.29%0.1M1.4M220.18K
2026-10-15-0.1M-219.59K
2026-09-307.47%0.1M0.8M218.82K
2026-09-15-0.1M-204.52K
2026-08-31-0.1M-189.93K
2026-08-14-0.0M-25.50K
2026-07-313.52%0.0M0.7M16.00K
2026-07-153.30%0.0M0.7M17.31K
2026-06-302.36%0.0M0.7M17.11K
2026-06-151.07%0.0M0.6M15.60K
2026-05-290.70%0.0M0.6M15.42K
2026-05-150.66%0.0M0.6M15.25K
2026-04-301.24%0.0M0.5M15.43K
2026-04-150.66%0.0M0.5M24.76K
2026-03-311.14%0.0M0.5M376.89K
2026-03-131.15%0.0M0.5M376.18K
2026-02-271.56%0.0M0.5M369.89K
2026-02-137.44%0.0M0.5M368.98K
2026-01-307.04%0.0M0.4M384.34K
2026-01-1532.30%0.1M0.4M367.61K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-30DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-30SEC
2026-10-21SCHEDULE 13G/ASEC
2026-10-20PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-20SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-13SEC
2026-10-088-KCurrent report2026-10-08SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-10-023Initial statement of beneficial ownership of securities2026-09-28SEC
2026-10-02SCHEDULE 13G/ASEC
2026-09-248-KCurrent report2026-09-23SEC
2026-08-24EFFECTEffectiveness filing by commission orderSEC
2026-08-24424B3SEC
2026-08-188-KCurrent report2026-08-13SEC
2026-08-17S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-314Statement of changes in beneficial ownership of securities2026-07-29SEC
2026-07-314Statement of changes in beneficial ownership of securities2026-07-29SEC
2026-07-318-KCurrent report2026-07-29SEC
2026-07-16SCHEDULE 13G/ASEC
2026-07-14SCHEDULE 13GSEC
2026-07-098-KCurrent report2026-07-09SEC
2026-06-268-KCurrent report2026-06-25SEC
2026-06-2610-KAnnual report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-06-228-KCurrent report2026-06-18SEC
2026-06-018-KCurrent report2026-05-28SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-05DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-05SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1048.86K200
2026-0913.49K200
2026-080000
2026-07225.00K200
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BALYASNY ASSET MANAGEMENT L.P.3.66%
Murchinson Ltd.2.16%
Daytona Street Capital LLC1.80%
GEODE CAPITAL MANAGEMENT, LLC0.88%
Bleichroeder LP0.68%
VANGUARD CAPITAL MANAGEMENT LLC0.49%
COMMONWEALTH EQUITY SERVICES, LLC0.37%
VANGUARD FIDUCIARY TRUST CO0.23%
BlackRock, Inc.0.17%
StoneX Group Inc.0.17%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.54%
VANGUARD EXTENDED MARKET INDEX FUND0.49%
Fidelity Nasdaq Composite Index Fund0.17%
Fidelity Total Market Index Fund0.04%
Fidelity Series Total Market Index Fund0.03%

OakChart. XAIR. Cached 15 minutes.